RBC Capital Initiates Epizyme With Outperform

Analysts at RBC Capital initiated coverage on Epizyme Inc EPZM with a Outperform rating. The target price for Epizyme is set to $40. Epizyme shares have dropped 29.99 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. Epizyme shares fell 2.45 percent to close at $22.71 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsRBC Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!